Please login to the form below

Not currently logged in
Email:
Password:

Quizartinib

This page shows the latest Quizartinib news and features for those working in and with pharma, biotech and healthcare.

Astellas, Catalyst approvals set up record year for FDA approvals

Astellas, Catalyst approvals set up record year for FDA approvals

Others are however moving through the late-stage pipeline, including Daiichi Sankyo’s quizartinib and Arog Pharma’s crenolanib.

Latest news

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    500. Ambit Biosciences / Daiichi Sankyo. Company acquisition. Kinase inhibitor pipeline, lead compound quizartinib for AML in phase III.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Similarly Daiichi Sankyo has supplemented its oncology pipeline by acquiring Ambit Biosciences for $400m. Ambit develops kinase inhibitors and has quizartinib in phase 3 for acute myeloid leukaemia.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics